Giloralimab

Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer[1][2].

Product Specifications

CAS Number

[2226292-20-0]

Product Name Alternative

ABBV-927

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/giloralimab.html

Purity

96.10

Solubility

10 mM in DMSO

Smiles

[Giloralimab]

Molecular Weight

(145.26 kDa)

References & Citations

[1]Boulard P, et al. Finding the Right Heavy Chains for Immunostimulatory Antibodies. Int J Mol Sci. 2022 Sep 8;23 (18) :10367.|[2]Peng L, et al. Novel immunotherapeutic drugs for the treatment of lung cancer. Curr Opin Oncol. 2022 Jan 1;34 (1) :89-94.